Last edition
News about "US FDA tentative marketing nod for epilepsy drug, "
Zydus Cadila gets US FDA tentative marketing nod for epilepsy drug, brivaracetam
Zydus Cadila has received tentative approval from the US FDA to market brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. Brivaracetam is used to treat partial-onset of seizures (epilepsy).
US FDA Tentative Marketing Nod For Epilepsy Drug, | 14/06/2021 | By Darshana | 146
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members